Zacks Investment Research upgraded shares of Trevena (NASDAQ:TRVN) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning, Zacks.com reports. They currently have $1.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
TRVN has been the topic of a number of other research reports. HC Wainwright set a $4.00 target price on shares of Trevena and gave the company a buy rating in a research note on Monday, June 24th. ValuEngine raised shares of Trevena from a sell rating to a hold rating in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $5.25.
Trevena (NASDAQ:TRVN) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. On average, research analysts forecast that Trevena will post -0.27 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Alpine Global Management LLC bought a new position in shares of Trevena in the first quarter worth approximately $31,000. A.R.T. Advisors LLC bought a new position in shares of Trevena in the second quarter worth approximately $36,000. D. E. Shaw & Co. Inc. bought a new position in shares of Trevena in the second quarter worth approximately $39,000. Jane Street Group LLC bought a new position in shares of Trevena in the second quarter worth approximately $51,000. Finally, Two Sigma Advisers LP lifted its stake in shares of Trevena by 35.3% in the fourth quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 16,400 shares in the last quarter. 23.50% of the stock is currently owned by institutional investors and hedge funds.
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.